바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.83 No.2
Citation Share

Protocol of a Nationwide Observational Study among Patients with Nontuberculous Mycobacterium Pulmonary Disease in South Korea (NTM-KOREA)

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2020, v.83 no.2, pp.141-146
https://doi.org/10.4046/trd.2019.0037
Nakwon Kwak (Seoul National University)
(Korean Institute of Tuberculosis)
Doosoo Jeon (Pusan National University)
Byung Woo Jhun (Sungkyunkwan University)

Young Ae Kang (Yonsei University)
Yong-Soo Kwon (Chonnam National University)
Myungsun Lee (International Tuberculosis Research Center)
Jeongha Mok (Pusan National University)

Hong-Joon Shin (Chonnam National University)
(Korean Institute of Tuberculosis)
Jae-Joon Yim (Seoul National University)
Nakwon, K. , Doosoo, J. , Byung, W. J. , Young, A. K. , Yong-Soo, K. , Myungsun, L. , Jeongha, M. , Hong-Joon, S. , & Jae-Joon, Y. (2020). Protocol of a Nationwide Observational Study among Patients with Nontuberculous Mycobacterium Pulmonary Disease in South Korea (NTM-KOREA). Tuberculosis & Respiratory Diseases, 83(2), 141-146, https://doi.org/10.4046/trd.2019.0037
  • Downloaded
  • Viewed
PDF Download

Abstract

Background: Infectious conditions may increase the risk of venous thromboembolism. The purpose of this study wasto evaluate the risk factor for combined infectious disease and its influence on mortality in patients with pulmonaryembolism (PE). Methods: Patients with PE diagnosed based on spiral computed tomography findings of the chest were retrospectivelyanalyzed. They were classified into two groups: patients who developed PE in the setting of infectious disease or thosewith PE without infection based on review of their medical charts. Results: Of 258 patients with PE, 67 (25.9%) were considered as having PE combined with infectious disease. The sites ofinfections were the respiratory tract in 52 patients (77.6%), genitourinary tract in three patients (4.5%), and hepatobiliarytract in three patients (4.5%). Underlying lung disease (odds ratio [OR], 3.69; 95% confidence interval [CI], 1.926–7.081;p<0.001), bed-ridden state (OR, 2.84; 95% CI, 1.390–5.811; p=0.004), and malignant disease (OR, 1.867; 95% CI, 1.017–3.425; p=0.044) were associated with combined infectious disease in patients with PE. In-hospital mortality was higher inpatients with PE combined with infectious disease than in those with PE without infection (24.6% vs. 11.0%, p=0.006). Inthe multivariate analysis, combined infectious disease (OR, 4.189; 95% CI, 1.692–10.372; p=0.002) were associated withnon-survivors in patients with PE. Conclusion: A substantial portion of patients with PE has concomitant infectious disease and it may contribute amortality in patients with PE.

keywords
Pulmonary Embolism, Infectious Disease, Mortality

Reference

1.

1. Henkle E, Hedberg K, Schafer S, Novosad S, Winthrop KL. Population-based incidence of pulmonary nontuberculous mycobacterial disease in Oregon 2007 to 2012. Ann Am Thorac Soc 2015;12:642-7.

2.

2. Koh WJ, Chang B, Jeong BH, Jeon K, Kim SY, Lee NY, et al. Increasing recovery of nontuberculous mycobacteria from respiratory specimens over a 10-year period in a tertiary referral hospital in South Korea. Tuberc Respir Dis 2013;75:199-204.

3.

3. Lee SK, Lee EJ, Kim SK, Chang J, Jeong SH, Kang YA. Changing epidemiology of nontuberculous mycobacterial lung disease in South Korea. Scand J Infect Dis 2012;44:733-8.

4.

4. Lee H, Myung W, Koh WJ, Moon SM, Jhun BW. Epidemiology of nontuberculous mycobacterial infection, South Korea, 2007-2016. Emerg Infect Dis 2019;25:569-72.

5.

5. Park YS, Lee CH, Lee SM, Yang SC, Yoo CG, Kim YW, et al. Rapid increase of non-tuberculous mycobacterial lung diseases at a tertiary referral hospital in South Korea. Int J Tuberc Lung Dis 2010;14:1069-71.

6.

6. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.

7.

7. Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 2017;72:ii1-64.

8.

8. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011;52:565-71.

9.

9. Adjemian J, Prevots DR, Gallagher J, Heap K, Gupta R, Griffith D. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc 2014;11:9-16.

10.

10. Kwak N, Park J, Kim E, Lee CH, Han SK, Yim JJ. Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis. Clin Infect Dis 2017;65:1077-84.

11.

11. Diel R, Ringshausen F, Richter E, Welker L, Schmitz J, Nienhaus A. Microbiological and clinical outcomes of treating non-Mycobacterium avium complex nontuberculous mycobacterial pulmonary disease: a systematic review and metaanalysis. Chest 2017;152:120-42.

12.

12. van Ingen J, Aksamit T, Andrejak C, Bottger EC, Cambau E, Daley CL, et al. Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. Eur Respir J 2018;51:1800170.

13.

13. Cook JL. Nontuberculous mycobacteria: opportunistic environmental pathogens for predisposed hosts. Br Med Bull 2010;96:45-59.

14.

14. Aliberti S, Codecasa LR, Gori A, Sotgiu G, Spotti M, Di Biagio A, et al. The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. Multidiscip Respir Med 2018;13(Suppl 1):33.

15.

15. Aksamit TR, O’Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels ML, et al. Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry. Chest 2017;151:982-92.

16.

16. Chalmers JD, Aliberti S, Polverino E, Vendrell M, Crichton M, Loebinger M, et al. The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Res 2016;2:00081-2015.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy